New Study Links Obstructive Sleep Apnea to Increased Risk of Mortality and Cardiovascular Events

Why It Matters

The findings confirm OSA as an independent driver of cardiovascular mortality and cost, urging earlier screening and integrated obesity‑OSA management to curb preventable deaths and expenses.

Key Takeaways

• OSA patients face 71% higher cardiovascular/mortality risk.
• 26.3% of OSA cohort hit events vs 17.5% controls.
• Study matched for obesity, smoking, comorbidities.
• OSA linked to new diabetes, obesity, mental‑health disorders.
• Healthcare use rises markedly for OSA patients.

Pulse Analysis

The European Congress on Obesity showcased the largest non‑U.S. matched case‑control investigation of obstructive sleep apnea to date, leveraging linked electronic health records from nearly 3 million residents. By pairing each OSA patient with up to five controls sharing age, socioeconomic status, smoking history and obesity status, researchers isolated the sleep disorder’s contribution to adverse outcomes. The resulting 71 percent relative risk increase—and a near‑ten‑point absolute gap in cardiovascular events or death—places OSA alongside hypertension and dyslipidemia as a critical, yet under‑addressed, cardiovascular risk factor.

Beyond the headline‑grabbing mortality data, the study mapped OSA’s ripple effects across metabolic and mental‑health domains. Participants free of disease at baseline were more likely to develop type 2 diabetes, obesity, osteoarthritis, anxiety and depression, underscoring the syndrome’s systemic inflammatory and neuroendocrine pathways. These associations reinforce calls for clinicians to embed sleep assessments within routine obesity and primary‑care visits, and to consider combined therapeutic strategies—such as CPAP alongside weight‑loss pharmacotherapies like tirzepatide—that target both airway obstruction and metabolic dysfunction.

From a health‑system perspective, OSA patients generated markedly higher primary‑care contacts, outpatient appointments and inpatient days, translating into measurable cost pressures. Policymakers and payers therefore have a financial incentive to fund broader screening programs, streamline diagnostic pathways, and expand coverage for effective treatments. As evidence mounts, guideline committees are likely to elevate OSA screening recommendations, especially for high‑risk groups, shaping a new standard of care that could reduce cardiovascular events, improve quality of life, and alleviate the economic burden of this pervasive sleep disorder.